Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found a significant relationship between the severity of androgenetic alopecia in men and a negative impact on their quality of life.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

This study developed a micellar electrokinetic capillary chromatography method for determining minoxidil in Rogaine and generic products, offering a simple and efficient alternative to HPLC.

Inherited ichthyosis negatively impacts quality of life, affecting daily activities, self-image, and reproductive decisions.

Medical questionnaires could modernize healthcare by improving access and efficiency but need guidelines to ensure quality care.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This report announces that the International Society of Hair Restoration Surgery received Accreditation with Commendation.

In this study, oral finasteride improved the quality of life for male patients with androgenetic alopecia, but it did not significantly reduce anxiety or correlate with reported anxiety levels.

This study found that high-charge-density cassia HPTC improves deposition efficiency and conditioning benefits in shampoos compared to quaternized guar, suggesting its potential as an alternative or adjunct conditioning agent.

This thesis reviews current therapeutic approaches for ARFID and provides preliminary insights into enhancing treatment and care in Australia, including an evaluation of a pilot dietetic-led cognitive-behavioral therapy intervention.

In this experimental study, researchers found that Notopterygii rhizoma et radix (Qiang Huo) significantly alleviated psoriasis symptoms in mice and cell models, primarily by modulating the PI3K/Akt/mTOR pathway, indicating potential as a multi-target alternative therapy for psoriasis treatment.

In a prospective observational study conducted in India, most adults with alopecia experienced quality of life impairment in the minimal-to-moderate range, with androgenetic alopecia being the most common subtype and minoxidil frequently prescribed, as reported by the researchers.

This study evaluated the safety and effectiveness of HASHA, a new hyaluronic acid injectable, for chin augmentation in adults with chin retrusion. HASHA significantly improved chin appearance and satisfaction over 12 months compared to controls, with only mild or moderate transient adverse events.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

In this analysis, Professor Ma Shuanquan attributes androgenetic alopecia to liver, spleen, and kidney dysfunctions and describes a treatment approach using Chinese medicines focused on these organs, suggesting individualization and noting significant therapeutic effects.

This study developed a high-throughput method that identifies bioactive chemicals influencing DHT production in prostate cancer cells, with potential nutraceutical candidates including fucoxanthin, phenethyl caffeate, and Curcuma longa L. extract.

This study developed a rapid method using advanced chromatography and mass spectrometry to detect hair-growth enhancing compounds, discovering synthetic drugs in about 21% of tested supplements.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study developed a rapid and efficient in vitro method using high-performance liquid chromatography to screen for steroid 5 alpha-reductase inhibitors, determining inhibition constants for Finasteride and Epristeride.

This study suggests that Gujian oral liquid may reduce osteoarthritis symptoms by regulating inflammation and catabolism through the TNF-α/NF-kappa B signaling pathway, as confirmed by both in vivo and in vitro experiments.

This study describes dissecting cellulitis of the scalp (DCS) as a rare and aggressive form of chronic scalp inflammation presenting with pustules and nodules, commonly affecting males and African Americans, and leading to significant quality of life impacts and psychological distress.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This case report describes a unique instance of a 6-year-old girl developing angioedema after treatment with squaric acid dibutylester for alopecia areata.

Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

In a mouse model of chemotherapy-induced alopecia, this study found that inhibiting the protein S100A8 with paquinimod alleviated hair loss and reduced oxidative stress and ferroptosis, suggesting a potential therapeutic strategy for managing this side effect in chemotherapy patients.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.